Travere Therapeutics Inc (TVTX)

28.63 +0.80 (+2.87%) USD  |  NASDAQ  |  Aug 08, 16:00
28.60 -0.03 (-0.10%) Pre-Market: 20:00
More

Travere Therapeutics News

News

Headline
Wire
Time (ET)
--HC Wainwright Adjusts Price Target on Travere Therapeutics to $42 From $46, Reiterates Buy Rating
MT Newswires
08/08 07:13
Travere Therapeutics Q2 Non-GAAP Loss Widens, Revenue Slips; Shares Fall
MT Newswires
08/04 09:29
Travere Therapeutics GAAP EPS of -$1.05 misses by $0.14, revenue of $54.2M beats by $4.7M
SA Breaking News
08/04 07:21
-- Earnings Flash (TVTX) TRAVERE THERAPEUTICS Reports Q2 Revenue $54.2M
MT Newswires
08/04 07:08
Travere Therapeutics Reports Second Quarter 2022 Financial Results
Globe Newswire
08/04 07:00
GBT, TVTX and NERV are among after hour movers
SA Breaking News
08/03 18:14
Travere Therapeutics Provides Regulatory Updates on its Development Programs
Globe Newswire
08/03 16:05
Travere Therapeutics to Report Second Quarter 2022 Financial Results
Globe Newswire
07/28 16:30
--Piper Sandler Adjusts Price Target on Travere Therapeutics to $41 From $40, Reiterates Overweight Rating
MT Newswires
07/26 07:43
Canaccord Genuity Assumes Travere Therapeutics at Buy with $42 Price Target
MT Newswires
07/14 12:00
Travere Theraspeutics a new buy at Canaccord as a 'rare disease powerhouse'
SA Breaking News
07/14 11:58
--Wedbush Lifts Price Target on Travere Therapeutics to $25 From $24, Maintains Neutral Rating
MT Newswires
07/14 07:36
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire
07/12 17:00
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo
07/12 17:00
Health Check: How Prudently Does Travere Therapeutics (NASDAQ:TVTX) Use Debt?
Yahoo
06/20 09:18
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire
06/14 17:00
Travere Therapeutics to Present at the 2022 Jefferies Healthcare Conference
Globe Newswire
06/02 16:30
Travere Therapeutics Announces Presentations of Abstracts at the 59th ERA Congress
Globe Newswire
05/17 16:30
HC Wainwright Adjusts Travere Therapeutics' Price Target to $46 From $45, Reiterates Buy Rating
MT Newswires
05/17 07:46
Travere Therapeutics Pops After Snagging Priority Review For A New Kidney Drug
Yahoo
05/16 16:09
Harpoon Therapeutics, Grove top healthcare gainers; Chimerix, Eliem lead losers' pack
SA Breaking News
05/16 10:03
Travere Therapeutics Says FDA Approves, Grants Priority Review for Sparsentan to Treat Kidney Disease
MT Newswires
05/16 09:31
Thinking about buying stock in AgriFORCE Growing Systems, Spirit Airlines, Travere Therapeutics, Data Storage, or Canoo?
PR Newswire
05/16 08:30
Travere Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Sparsentan for the Treatment of IgA Nephropathy
Globe Newswire
05/16 07:00
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo
05/11 17:00
-- Earnings Flash (TVTX) TRAVERE THERAPEUTICS Posts Q1 Revenue $48.5M, vs. Street Est of $51.9M
MT Newswires
05/05 16:07
Travere Therapeutics Reports First Quarter 2022 Financial Results
Globe Newswire
05/05 16:01
Travere Therapeutics to Present at the BofA Securities 2022 Healthcare Conference
Globe Newswire
05/03 16:30
Travere Therapeutics to Report First Quarter 2022 Financial Results
Globe Newswire
04/28 16:30
--Wedbush Cuts Price Target on Travere Therapeutics to $24 From $27, Maintains Neutral Rating
MT Newswires
04/28 07:14
Travere Therapeutics Names Chris Cline CFO
MT Newswires
04/20 17:00
Travere Therapeutics Announces Plan for Chief Financial Officer Transition
Globe Newswire
04/20 16:30
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire
04/12 17:00
Piper Sandler Starts Travere Therapeutics at Overweight With $42 Price Target
MT Newswires
03/31 01:37
Travere Therapeutics Submits New Drug Application for Sparsentan for the Treatment of IgA Nephropathy
Globe Newswire
03/21 07:00
TCOM, OSUR and ARCT among after hour movers
SA Breaking News
03/17 17:59
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire
03/14 17:00
Travere prices upsized $275M convertible senior notes offering
SA Breaking News
03/09 03:27
Travere Therapeutics Prices Upsized $275 Million Senior Notes Offering
MT Newswires
03/09 03:02
Update: Travere Therapeutics Plans Senior Note Offering -- Shares Decline
MT Newswires
03/08 12:34
Voyager, 908 Devices top healthcare gainers; Alector, Can-Fite BioPharma lead losers' pack
SA Breaking News
03/08 10:04
Sector Update: Health Care Stocks Post Slight Gains Premarket Tuesday
MT Newswires
03/08 09:03
Travere Therapeutics Plans $250 Million Senior Notes Offering
MT Newswires
03/08 07:33
Travere Announces Proposed Convertible Senior Notes Offering
Globe Newswire
03/08 07:00
Travere Therapeutics to Present at the Barclays Global Healthcare Conference
Globe Newswire
03/03 16:30
HC Wainwright Starts Travere Therapeutics at Buy With $45 Price Target
MT Newswires
02/28 08:06
Travere Therapeutics Recognizes Rare Disease Day 2022 and Raises Awareness for People Living with Rare Disease
Globe Newswire
02/28 08:00
-- Earnings Flash (TVTX) TRAVERE THERAPEUTICS Posts Q4 Revenue $57.2M, vs. Street Est of $57.0M
MT Newswires
02/24 16:12
Travere Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Globe Newswire
02/09 16:30
Wedbush Lifts Travere Therapeutics' Price Target to $27 From $25, Maintains Neutral Rating
MT Newswires
01/25 09:00
Insider Sell: Travere Therapeutics
MT Newswires
01/12 17:15
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire
01/12 17:00
Travere Therapeutics sees FY2021 revenue above consensus
SA Breaking News
01/10 13:36
Travere Therapeutics Expects Q4 Net Product Sales of $55 Million
MT Newswires
01/10 07:54
Travere Therapeutics Provides Corporate Update and 2022 Outlook
Globe Newswire
01/10 07:00
Travere Therapeutics Names Jula Inrig Chief Medical Officer
MT Newswires
01/04 16:41
Travere Therapeutics Appoints Jula Inrig, M.D., as Chief Medical Officer
Globe Newswire
01/04 16:30
--Barclays Adjusts Price Target for Travere Therapeutics to $40 From $36, Maintains Overweight Rating
MT Newswires
12/16 08:50
SVB Leerink Adjusts Travere Therapeutics' Price Target to $42 from $37, Keeps Outperform Rating
MT Newswires
12/16 08:48
Wedbush Lifts Travere Therapeutics' Price Target to $25 From $20 on Pegtibatinase Data, Maintains Neutral Rating
MT Newswires
12/16 05:17
Travere Therapeutics Says Classical Homocystinuria Drug Reduces Blood Levels of Homocysteine in Early-Stage Trial
MT Newswires
12/15 07:35
Insider Sell: Travere Therapeutics
MT Newswires
11/09 17:22
Insider Sell: Travere Therapeutics
MT Newswires
11/03 17:58
Travere Therapeutics' Q3 Adjusted Loss Widens, Revenue Grows
MT Newswires
10/29 11:03
--Wedbush Lifts Price Target on Travere Therapeutics to $20 From $14, Maintains Neutral Rating
MT Newswires
10/29 07:44
-- Earnings Flash (TVTX) TRAVERE THERAPEUTICS Reports Q3 Revenue $68.2M, vs. Street Est of $60.9M
MT Newswires
10/28 16:02
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire
10/13 17:00
Travere Therapeutics Chief Medical Officer to Shift to Adviser Role at Yearend
MT Newswires
10/12 17:11
Travere Therapeutics Announces Transition of Chief Medical Officer
Globe Newswire
10/12 17:00
Insider Sell: Travere Therapeutics
MT Newswires
10/08 16:29
Wedbush Adjusts Travere Therapeutics PT to $14 From $15, Maintains Neutral Rating
MT Newswires
09/16 11:50
Travere Therapeutics, Vifor Pharma Enter Licensing Deal for Commercialization of Sparsentan
MT Newswires
09/16 04:41
LAUR, LPTX, AERI and TWKS among after hours movers
SA Breaking News
09/15 17:44
Travere Therapeutics Appoints Kaiser Foundation Executive Ruth Williams-Brinkley to Board
MT Newswires
09/14 16:50
Travere Therapeutics Appoints Ruth Williams-Brinkley to its Board of Directors
Globe Newswire
09/14 16:30
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire
09/13 17:00
Travere Therapeutics, FDA Find Regulatory Pathway for Sparsentan in Focal Segmental Glomerulosclerosis
MT Newswires
09/07 10:08
Travere Therapeutics Announces Successful Outcome from Type A Meeting with U.S. FDA for Sparsentan in Focal Segmental Glomerulosclerosis
Globe Newswire
09/07 08:00
ANAB, TLRY, PFMT and BMRN among after hours movers
SA Breaking News
08/17 17:39
--SVB Leerink Adjusts Travere Therapeutics' Price Target to $37 From $27, Keeps Outperform Rating
MT Newswires
08/17 07:25
Sector Update: Health Care Stocks Add to Monday Gains
MT Newswires
08/16 15:52
Sector Update: Health Care Stocks Rising in Defensive Trading
MT Newswires
08/16 13:39
ASRT, GOCO, AEYE among mid-day movers
SA Breaking News
08/16 12:38
Wall Street Set for Narrow Losses; Weak China Data, Turmoil in Afghanistan Weigh on Sentiment
MT Newswires
08/16 09:19
Sector Update: Health Care Stocks Mixed Pre-Bell Monday
MT Newswires
08/16 09:14
Travere Therapeutics' Kidney Disease Drug Meets Phase 3 Trial Main Goal in Interim Results
MT Newswires
08/16 08:34
Thinking about buying stock in Travere Therapeutics, ADMA Biologics, Surgalign, CTI BioPharma, or OpGen?
PR Newswire
08/16 08:30
Top Premarket Gainers
MT Newswires
08/16 08:10
--Wedbush Adjusts PT on Travere Therapeutics to $15 From $19 on Capital Raise Expectations, Lowered Legacy Franchise Estimates; Neutral Rating Kept
MT Newswires
07/30 06:45
-- Earnings Flash (TVTX) TRAVERE THERAPEUTICS Posts Q2 Revenue $54.6M, vs. Street Est of $50.3M
MT Newswires
07/29 16:03
Travere Therapeutics Reports Second Quarter 2021 Financial Results
Globe Newswire
07/29 16:01
Travere Therapeutics to Report Second Quarter 2021 Financial Results
Globe Newswire
07/22 16:30
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire
07/14 16:30
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
Globe Newswire
06/07 22:47
Travere Therapeutics Announces Presentation of Abstracts at ERA-EDTA Congress 2021
Globe Newswire
06/04 08:00
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
Globe Newswire
06/02 23:01
Travere Therapeutics Completes Patient Enrollment for Late-Stage Study of Sparsentan in Rare Kidney Disorder
MT Newswires
06/02 09:04
Travere Therapeutics Completes Enrollment in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
Globe Newswire
06/02 08:00
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
PR Newswire
06/01 05:35
Travere Therapeutics to Present at Upcoming Investor Conferences
Globe Newswire
05/27 16:30
Canaccord Genuity Adjusts Price Target on Travere Therapeutics to $45 From $48, Maintains Buy Rating
MT Newswires
05/27 11:27
Path for Travere's Sparsentan in Focal Segmental Glomerulosclerosis Lacks Regulatory Clarity, Wedbush Says
MT Newswires
05/26 16:03
Midday Report: Wall Street Higher Midday, Led by Clothing Retailers
MT Newswires
05/26 12:46
ASXC, SOL, LPCN and ABCL among midday movers
SA Breaking News
05/26 12:38
SVB Leerink Adjusts Price Target on Travere Therapeutics to $27 From $35, Keeps Outperform Rating
MT Newswires
05/26 11:29
Evercore ISI Adjusts Price Target on Travere Therapeutics to $23 From $30, Keeps Outperform Rating
MT Newswires
05/26 11:29
BMO Capital Adjusts Price Target on Travere Therapeutics to $33 From $38, Keeps Outperform Rating
MT Newswires
05/26 11:29
Asensus Surgical, Nabriva Therapeutics leads healthcare gainers; Larimar Therapeutics, Travere Therapeutics among major losers
SA Breaking News
05/26 11:02
Sector Update: Health Care Stocks Mixed Premarket Wednesday
MT Newswires
05/26 09:12
Agilent price target lifted after guidance raise, Travere downgraded on regulatory update; more in today’s analyst action
SA Breaking News
05/26 09:04
RLX Technology, Nordstrom among premarket losers' pack
SA Breaking News
05/26 08:27
Barclays Adjusts Price Target on Travere Therapeutics to $34 From $40, Maintains Overweight Rating
MT Newswires
05/26 06:54
Wedbush Cuts Travere Therapeutics to Neutral From Outperform, PT to $19 From $37 on Sparsentan/FSGS Regulatory Update
MT Newswires
05/26 06:45
Travere Therapeutics Says Accelerated Approval for Sparsentan in Focal Segmental Glomerulosclerosis Unexpected This Year
MT Newswires
05/26 06:12
NBRV, SELB, ANPC and TVTX among after-hours movers
SA Breaking News
05/25 17:42
Travere Therapeutics shares fall on sparsentan development program regulatory update
SA Breaking News
05/25 16:06
Travere Therapeutics Provides Regulatory Update on Sparsentan Development Program for Focal Segmental Glomerulosclerosis
Globe Newswire
05/25 16:01
--Canaccord Genuity Adjusts Price Target on Travere Therapeutics to $48 From $51, Maintains Buy Rating
MT Newswires
05/17 10:34
Travere defended despite generic competition, Elanco remains a buy at Citi; in today’s analyst action
SA Breaking News
05/17 08:43
Travere tumbles as Teva bags FDA approval for generic of Thiola
SA Breaking News
05/14 11:56
--BMO Capital Adjusts Price Target on Travere Therapeutics to $38 From $43, Keeps Outperform Rating
MT Newswires
05/07 13:58
--Wedbush Adjusts Price Target on Travere Therapeutics to $37 From $39 on 2021 Expense Estimates, Keeps Outperform Rating
MT Newswires
05/07 07:28
-- Earnings Flash (TVTX) TRAVERE THERAPEUTICS Reports Q1 Revenue $47.4M, vs. Street Est of $50.1M
MT Newswires
05/06 16:06
-- Earnings Flash (TVTX) TRAVERE THERAPEUTICS Reports Q1 Loss $-0.55, vs. Street Est of $-0.31
MT Newswires
05/06 16:05
Travere Therapeutics Reports First Quarter 2021 Financial Results
Globe Newswire
05/06 16:01
Travere Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference
Globe Newswire
04/27 16:30
Travere Therapeutics to Report First Quarter 2021 Financial Results
Globe Newswire
04/26 16:30
--Analyst Actions: BMO Capital Adjusts Price Target on Travere Therapeutics to $43 From $48, Maintains Outperform Rating
MT Newswires
03/02 11:05
Travere Therapeutics Q4 Non-GAAP Loss Widens, Revenue Rises
MT Newswires
03/01 17:04
-- Earnings Flash (TVTX) TRAVERE THERAPEUTICS Reports Q4 Revenue $50.98M, vs. Street Est of $51.2M
MT Newswires
03/01 16:02
Travere Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
Globe Newswire
03/01 16:01
Travere Therapeutics Recognizes Rare Disease Day 2021 and the Importance of Working Together to Innovate and Address Healthcare Disparities in Rare Disease
Globe Newswire
02/25 08:00
Travere Therapeutics to Present at Upcoming Investor Conferences
Globe Newswire
02/22 16:30
Travere Therapeutics Announces European Commission Has Granted Orphan Designation to Sparsentan for the Treatment of IgA Nephropathy
Globe Newswire
02/18 16:30
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
Globe Newswire
02/17 16:05
Travere Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results
Globe Newswire
02/16 16:30
Travere Therapeutics Prices Common Stock Offering at $26.75 Per Share
MT Newswires
02/12 04:59
Travere Therapeutics to raise $150M through public offering
SA Breaking News
02/10 16:06
Travere Therapeutics Announces Proposed Public Offering of Common Stock
Globe Newswire
02/10 16:01
--Analyst Actions: Wedbush Adjusts Travere Therapeutics' Price Target to $46 From $38, Maintains Outperform Rating
MT Newswires
02/02 14:06
Ligand and Travere announce promising data from late-stage sparsentan trial
SA Breaking News
02/02 12:45
Travere meets interim efficacy endpoint for sparsentan in rare kidney disorder
SA Breaking News
02/02 11:30
Travere Therapeutics' Late-Stage Study of Potential Treatment for Kidney Disease Meets Endpoint
MT Newswires
02/02 11:03
Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
Globe Newswire
02/02 07:00
Travere Therapeutics Obtains FDA Orphan Drug Designation for Sparsentan for Kidney Disorder
MT Newswires
01/12 16:53
Travere Therapeutics' sparsentan an Orphan Drug in U.S. for rare kidney disease
SA Breaking News
01/12 16:50
Travere Therapeutics Announces Orphan Drug Designation for Sparsentan for the Treatment of IgA Nephropathy
Globe Newswire
01/12 16:30
Travere Provides Q4, FY20 Net Product Sales Guidance About In Line With Analysts' Estimates
MT Newswires
01/11 15:20
Travere Therapeutics reports preliminary 4Q20 revenue of $51M
SA Breaking News
01/11 10:42
Travere Therapeutics Provides Corporate Update and 2021 Outlook
Globe Newswire
01/11 07:00
Travere Therapeutics to Host Virtual R&D Day on Wednesday, December 9, 2020
Globe Newswire
12/01 16:30
Travere Therapeutics Enrolls Last Patients for Late-Stage Trial of Prospective Kidney Drug
MT Newswires
11/30 16:46
Retrophin Changes Name to Travere Therapeutics
MT Newswires
11/16 11:39
Retrophin Announces Corporate Name Change to Travere Therapeutics, Inc.
Globe Newswire
11/16 08:00
Retrophin Completes Acquisition of Orphan Technologies
Globe Newswire
11/12 16:05
Retrophin to Present at Upcoming Investor Conferences
Globe Newswire
11/11 16:30
--Analyst Actions: BMO Capital Adjusts Retrophin's Price Target to $33 from $31, Keeps Outperform Rating
MT Newswires
11/06 13:08
--Analyst Actions: Wedbush Adjusts Retrophin's Price Target to $36 From $33, Keeps Outperform Rating
MT Newswires
11/06 09:24
-- Earnings Flash (RTRX) RETROPHIN Reports Q3 Revenue $51.1M, vs. Street Est of $47.8M
MT Newswires
11/05 17:08
Retrophin Reports Third Quarter 2020 Financial Results
Globe Newswire
11/05 16:01
Retrophin Announces Agreement to Acquire Orphan Technologies
Globe Newswire
10/22 16:01
Retrophin to Report Third Quarter 2020 Financial Results
Globe Newswire
10/21 16:30
Retrophin, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire
10/14 17:00
Retrophin Announces Presentation of Abstracts at ASN Kidney Week 2020 Reimagined
Globe Newswire
10/09 16:01
Retrophin Enrolls 280 Patients in Phase 3 Study Of Treatment for Kidney Disease
MT Newswires
09/21 15:12
Retrophin enrolls patients for the study of sparsentan in IgA nephropathy
SA Breaking News
09/21 08:57
Retrophin Announces Enrollment of First 280 Patients in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
Globe Newswire
09/21 08:00
Analyst Actions: Wedbush Starts Retrophin at Outperform With $33 Price Target
MT Newswires
09/18 06:57
Retrophin, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire
09/14 17:00
BofA bullish on Retrophin, sees 56% upside
SA Breaking News
08/24 13:08
Analyst Actions: BofA Securities Starts Retrophin at Buy With $30 Price Target
MT Newswires
08/24 08:15
Retrophin to Present at Upcoming Investor Conferences
Globe Newswire
08/03 16:30
-- Earnings Flash (RTRX) RETROPHIN INC. Reports Q2 Revenue $48.43M, vs. Street Est of $47.6M
MT Newswires
07/30 16:08
Retrophin EPS beats by $0.14, beats on revenue
SA Breaking News
07/30 16:04
Retrophin Reports Second Quarter 2020 Financial Results
Globe Newswire
07/30 16:01
Retrophin to Report Second Quarter 2020 Financial Results
Globe Newswire
07/16 16:30
Retrophin to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
Globe Newswire
06/19 08:00
--Analyst Actions: BTIG Initiates Coverage on Retrophin at Buy With $25 Price Target
MT Newswires
06/17 08:09
Retrophin Prices Common Stock Offering At $15.50 Per Share
MT Newswires
06/09 06:38
Retrophin prices equity offering at $15.50
SA Breaking News
06/09 04:54
Retrophin Announces Pricing of Public Offering of Common Stock
Globe Newswire
06/08 22:02
Retrophin Plans to Launch Public Offering of Common Stock
MT Newswires
06/08 16:15
Retrophin launches equity offering
SA Breaking News
06/08 16:08
Retrophin Announces Proposed Public Offering of Common Stock
Globe Newswire
06/08 16:01
Retrophin to Present at the Jefferies 2020 Virtual Healthcare Conference
Globe Newswire
05/27 16:30
Analyst Actions: BMO Capital Lifts Retrophin's Price Target to $34 From $33, Keeps Outperform Rating
MT Newswires
05/12 12:15
Retrophin Q1 Adj. Net Loss Narrows From Year Ago, Revenue Climbs
MT Newswires
05/11 17:06
Retrophin Reports First Quarter 2020 Financial Results
Globe Newswire
05/11 16:01
Earnings Reaction History: RETROPHIN INC, 66.7% Follow-Through Indicator, 6.5% Sensitive
MT Newswires
05/11 14:20
Retrophin to Report First Quarter 2020 Financial Results
Globe Newswire
04/27 16:30
Retrophin Appoints Suzanne L. Bruhn, Ph.D. to Board of Directors
Globe Newswire
04/09 16:30
Retrophin Advances Pivotal Study of Potential Kidney Scarring Cure With Enrollment of First 190 Patients
MT Newswires
03/09 09:17
Retrophin Announces Enrollment of First 190 Patients in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
Globe Newswire
03/09 08:00
Retrophin Recognizes Rare Disease Day 2020 and the Importance of Working Together Toward More Equitable Access to Care
Globe Newswire
02/28 08:00
Analyst Actions: Barclays Downgrades Retrophin to Equal-Weight From Overweight; Price Target is $19
MT Newswires
02/25 08:15
MT Newswires After-Hours News Movers
MT Newswires
02/24 17:53
Retrophin Q4 Non-GAAP Loss Better Than Estimates, Revenue in Line With Street View
MT Newswires
02/24 16:19
Retrophin EPS beats by $0.11, beats on revenue
SA Breaking News
02/24 16:03
Retrophin Reports Fourth Quarter and Full Year 2019 Financial Results
Globe Newswire
02/24 16:01
Earnings Reaction History: RETROPHIN INC, 50.0% Follow-Through Indicator, 5.3% Sensitive
MT Newswires
02/24 15:00
Retrophin to Present at Upcoming Investor Conferences
Globe Newswire
02/19 16:30
Retrophin, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire
02/13 17:00
Retrophin to Report Fourth Quarter and Full Year 2019 Financial Results
Globe Newswire
02/10 16:30
Retrophin Q4, FY19 Estimates Exceed Street Views
MT Newswires
01/13 17:50
Retrophin Provides Corporate Update and 2020 Outlook
Globe Newswire
01/13 06:59
Retrophin to Present at the Jefferies 2019 London Healthcare Conference
Globe Newswire
11/14 16:30
Retrophin Q3 Loss Wider than Expected, Misses on Revenue
MT Newswires
10/30 16:15
Retrophin Reports Third Quarter 2019 Financial Results
Globe Newswire
10/30 16:01
Retrophin to Report Third Quarter 2019 Financial Results
Globe Newswire
10/16 16:30
Retrophin Announces Presentation of Abstracts at ASN Kidney Week 2019
Globe Newswire
10/11 16:05
Retrophin Names New Chief Commercial Officer
MT Newswires
10/01 16:44
Retrophin appoints Amgen vet as first CCO
SA Breaking News
10/01 16:39
Retrophin Announces Appointment of Peter Heerma as Chief Commercial Officer
Globe Newswire
10/01 16:30
Retrophin to Present at the 2019 Cantor Global Healthcare Conference
Globe Newswire
09/26 16:30
BioMarin readies study of gene therapy for PKU
SA Breaking News
09/26 10:14
Adamas Pharmaceuticals Names Former Retrophin Executive as CEO
MT Newswires
09/13 07:59
Analyst Actions: Barclays Cuts Retrophin Price Target to $20 From $36, Maintains Overweight Rating
MT Newswires
08/23 11:51
Analyst Actions: BMO Capital Cuts Retrophin Price Target to $33 From $38, Maintains Outperform Rating
MT Newswires
08/23 11:51
--Analyst Actions: Retrophin's PT Cut to $23 From $38 at Canaccord Genuity on Fosmetpantotenate Trial Failure, Buy Rating Reiterated
MT Newswires
08/23 10:42
--Analyst Actions: Retrophin's PT Cut to $33 From $57 at Nomura on Fosmetpantotenate Discontinuation, Buy Rating Reiterated
MT Newswires
08/23 09:26
Close Update: Dow Lone Index to Close Higher as Nasdaq, S&P 500 Slip Ahead of Powell Speech
MT Newswires
08/22 16:29
Sector Update: Small Drop for Health Care Stocks This Afternoon
MT Newswires
08/22 15:54
Sector Update: Health Care Stocks Weaker Thursday Afternoon
MT Newswires
08/22 13:44
Stock Move: Retrophin Shares Plunge 26% After Trial of Fosmetpantotenate Fails to Meet Endpoints
MT Newswires
08/22 12:53
BJ, FLWS, JWN, PSTG, SPLK and YJ among midday movers
SA Breaking News
08/22 12:40
Healthcare - Top 5 Gainers / Losers
SA Breaking News
08/22 11:00
Wall Street Sees Cautiously Higher Open Ahead of Jackson Hole Meeting
MT Newswires
08/22 09:16
SQM, RTRX among premarket losers
SA Breaking News
08/22 09:11
Sector Update: Health Care Giants Mostly Flat Pre-Market Thursday
MT Newswires
08/22 09:10
Retrophin's fosmetpantotenate flunks late-stage study in rare neurodegenerative disorder; shares down 25% premarket
SA Breaking News
08/22 07:08
Retrophin Says Trial of Fosmetpantotenate to Treat Neurological Disorder Fails to Meet Endpoints
MT Newswires
08/22 06:58
Retrophin Announces Topline Results from Phase 3 FORT Study of Fosmetpantotenate in Patients with PKAN
Globe Newswire
08/22 06:00
Retrophin Reports Second Quarter 2019 Financial Results
Globe Newswire
08/06 16:01
Notable earnings after Tuesday’s close
SA Breaking News
08/05 17:35
Retrophin Q2 2019 Earnings Preview
SA Breaking News
08/05 17:35
Retrophin to Present at Canaccord Genuity’s 39th Annual Growth Conference
Globe Newswire
07/31 16:30
Retrophin to Report Second Quarter 2019 Financial Results
Globe Newswire
07/23 16:30
--Analyst Actions: Retrophin's PT Raised to $41 From $37 at Canaccord on Approval of New Thiola, Buy Rating Reiterated
MT Newswires
07/01 12:40
AG, WPX, HEB and KEG among notable after hour movers
SA Breaking News
06/28 17:49
Retrophin Wins FDA Ok of Thiola EC 100mg and 300mg Tablets for Cystinuria; Shares Rise After-Hours
MT Newswires
06/28 16:40
FDA OKs Retrophin's Thiola for cystinuria; shares up 3% after hours
SA Breaking News
06/28 16:40
Retrophin Announces FDA Approval of THIOLA® EC (tiopronin) 100mg and 300mg Tablets for the Treatment of Cystinuria
Globe Newswire
06/28 16:34
Retrophin Settles All Disputes With Jailed Former CEO Martin Shkreli -- Shares Up More Than 1%
MT Newswires
06/20 15:10
Retrophin, Shkreli settle lawsuit - CNBC
SA Breaking News
06/20 13:06
Retrophin in CRADA to focus on Alagille syndrome
SA Breaking News
06/18 16:44
Retrophin Announces Cooperative Research and Development Agreement with NCATS and the Alagille Syndrome Alliance to Identify Potential Therapeutics for Alagille Syndrome
Globe Newswire
06/18 16:30
Retrophin to Present at Upcoming Investor Conferences
Globe Newswire
05/30 16:30
Retrophin Appoints Sandra E. Poole to Board of Directors
Globe Newswire
05/13 08:00
Retrophin Reports First Quarter 2019 Financial Results
Globe Newswire
05/07 16:01
Earnings Reaction History: RETROPHIN INC, 66.7% Follow-Through Indicator, 4.7% Sensitive
MT Newswires
05/07 14:04